# Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

> **NCT02045264** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 12 (actual)

## Conditions studied

- Hereditary Angioedema (HAE)

## Interventions

- **DRUG:** Icatibant (30 mg)

## Key facts

- **NCT ID:** NCT02045264
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-21
- **Primary completion:** 2014-02-27
- **Final completion:** 2014-02-27
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045264, "Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02045264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*